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5Introductory note and acknowledgements
In-depth reviews of topical interest are published as Selected issues each year. These reports are based on information 
provided to the EMCDDA by the EU Member States and candidate countries and Norway (participating in the work of the 
EMCDDA since 2001) as part of the national reporting process.
The most recent Selected issues are:
•  Trends in injecting drug use in Europe;
•  Drug offences: sentencing and other outcomes;
•  Polydrug use: patterns and responses.
All Selected issues (in English) and summaries (in up to 23 languages) are available on the EMCDDA website: 
http://www.emcdda.europa.eu/publications/selected-issues
The EMCDDA would like to thank the following for their help in producing this Selected issue:
•  the heads of Reitox national focal points and their staff;
•  the services within each Member State that collected the raw data;
•  the members of the Management Board and the Scientific Committee of the EMCDDA;
•  the Publications Office of the European Union.
Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The network is comprised of national focal points in the EU 
Member States, Norway, the candidate countries and at the European Commission. Under the responsibility of their governments, 
the focal points are the national authorities providing drug information to the EMCDDA.
The contact details of the national focal points may be found at: 
http://www.emcdda.europa.eu/index.cfm?nnodeid=403

7Introduction
Amphetamine and methamphetamine are two closely 
related synthetic substances that act as stimulants of the 
central nervous system. They can be ingested, snorted or 
injected, and methamphetamine, particularly in its crystalline 
form, can be smoked. The two substances can be so similar 
in their effects and appearance that often the user cannot 
tell them apart. Their effects include elevated mood; a sense 
of well-being; increased energy, wakefulness, concentration, 
alertness, and motor and speech activities; improved 
performance in physical and mental tasks; and reduced 
fatigue. Among other effects viewed by users as positive 
and rewarding are decreased social or sexual inhibitions, 
and the desire to lengthen social interactions or to socialise 
with others using the drug. This broad range of effects might 
explain why the use of amphetamines has been reported 
among many different population groups including soldiers, 
workers (e.g. truck or taxi drivers, hospital staff), students, 
sex workers, clubbers or problem heroin users. 
Of the main illicit drugs, the patterns and geography of 
amphetamines (1) use in Europe are among the most difficult 
to describe. There are several reasons for this. First, the 
prevalence of amphetamines use varies greatly between 
countries. The diversity of user groups is possibly one of the 
largest of all illicit substances found in Europe. In addition, a 
small number of countries have problem amphetamines use 
at the heart of their drug problem and, when this is the case, 
it has very specific socio-historical and epidemiological 
characteristics. The stimulant market in Europe also appears 
to be changing frequently, particularly in nightlife settings, 
with shifts in popularity between substances such as 
amphetamines, cocaine, ecstasy, piperazines or new 
stimulant drugs such as mephedrone. Finally, Europe is an 
important producer of amphetamines with several countries 
reporting illicit production facilities on their territory.
The provision of care for those with amphetamines problems 
is another area in which differences exist between countries. 
In general, treatment services are more attuned to the needs 
of amphetamines users in the countries where problematic 
use of these substances is longer established, while 
elsewhere services are targeted to the needs of the largest 
group of problem drug users (2), mostly opioid users. 
Organised in two parts, this Selected issue aims to provide 
a comprehensive overview of the history, health effects, 
supply and use of amphetamines in Europe, as well as 
describing their problematic use and the responses to them 
in the European countries that are most heavily affected. The 
first part begins with a short history of the use of these drugs 
and a presentation of the laws that are used to control them. 
This is followed by an analysis of drug supply information, 
mainly from police and customs services. The next section 
gives an overview of the prevalence of amphetamines use in 
the Europe population. The last section of Part I covers the 
mental and physical health effects of amphetamines use, 
including a review of the information on infectious diseases 
and deaths related to these drugs. In Part 2, countries are 
grouped in four geographical regions and sub-regions 
according to their amphetamines problems, with particular 
attention given to those with significant levels of problem 
amphetamines use. Treatment responses to amphetamines 
problems are also described for the different countries or 
groups of countries.
Problem amphetamine and methamphetamine use in Europe
(1) Here, amphetamine and methamphetamine are referred to collectively as amphetamines.
(2)  Problem drug use is defined as ‘injecting drug use or long-duration/regular use of opioids, cocaine and/or amphetamines’; for more information see the 
EMCDDA website.
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Data and focus of this report
This Selected issue is based on data routinely collected by the 
EMCDDA, reports in the scientific literature as well as a special 
data collection in 14 countries in which amphetamines use is 
particularly relevant in the national drug situation (1). Therefore, 
some of the information presented in this report covers the 27 
EU Member States, Norway and the candidate countries 
Croatia and Turkey, while other sections focus on all or some of 
the 14 countries that reported data for this Selected issue. 
Much of the information on which this Selected issue is based is 
published in the national languages of the reporting countries, 
and has been reported to the EMCDDA as part of the 2009 
National reports provided by each country. In general, these 
sources are not explicitly referred to in the text of this 
publication, but the reader can refer to the Reitox National 
reports, available online on the EMCDDA website, for a full list 
of sources. 
(1)  Belgium, Czech Republic, Estonia, Latvia, Luxembourg, Hungary, 
Netherlands, Poland, Slovakia, Finland, Sweden, United Kingdom, 
Croatia, Norway.
Countries providing additional data
Countries not providing additional
data, but with evidence of problem 
amphetamines use
9Historical background
Amphetamine was first synthesised in Germany in 1887, 
methamphetamine powder in 1893 and crystal 
methamphetamine in 1918/19 in Japan. Widespread 
medicinal use of the drugs in Europe appears to date from 
the 1930s, with the introduction of benzedrine 
(amphetamine) and pervitin (methamphetamine) as over-the-
counter medicines. The stimulatory effects of these 
substances on the central nervous system were soon 
recognised, and amphetamine and methamphetamine 
tablets were widely distributed to troops during the Second 
World War. 
In the 1940s and 1950s, as accounts about side-effects and 
addiction surfaced, countries attempted to restrict the 
availability of amphetamines by making them prescription 
drugs. In the 1960s, recreational amphetamines use reached 
high levels among some sub-populations in parts of Europe. 
Control measures culminated in the 1970s with the adoption 
at UN level of the International Convention on Psychotropic 
Substances (3).
Together with the control measures on amphetamines, the 
arrival of heroin on the drugs market saw the use of 
amphetamines dwindle in most western European countries, 
as problem drug users switched over to heroin. In 
Scandinavian countries, however, amphetamines retained 
their popularity. While amphetamines were still available as 
prescription drugs in Czechoslovakia in the 1970s, 
manufacturing in kitchen labs and injecting of 
methamphetamine emerged. In what is now the Czech 
Republic, small closed groups of users organised around 
methamphetamine producers, and by the late 1980s most 
people who were dependent on drugs other than alcohol 
were pervitin users. 
In the 1990s, the emergence of the electronic music scene 
led to a rise in amphetamines use in recreational settings, 
though the prevalence of problem use of the drug remained 
low. Toward the close of that decade, countries in the north 
of Europe experienced another wave of amphetamines use, 
with problem amphetamines users outnumbering problem 
opioid users. Indications of amphetamines use appeared in 
the Baltic States and Poland only in the 1990s, since when it 
has increased. In much of southern Europe, amphetamines 
have never been among the most prevalent drugs. Current 
patterns of supply and demand in Europe reflect the history 
of amphetamines in the region.
Legislation
Synthetic psychoactive substances are controlled 
internationally by the United Nations Convention on 
Psychotropic Substances of 1971, which lists them in four 
Schedules requiring different levels of control. Amphetamine 
and methamphetamine are listed in Schedule II, which 
contains ‘substances whose liability to abuse constitutes a 
substantial risk to public health and which have little to 
moderate therapeutic usefulness’ (UN, 1976). In the 
European Union, these substances are classified as illicit 
drugs in all Member States. 
About half of the European Union’s Member States have 
laws that set out the same penalty for all drugs, whereas 
others vary the level of penalty available for the substance 
according to the level of harm it may cause (regardless of 
any therapeutic value). A distinction between drugs may 
also be made depending on the offence; penalties may be 
equal for personal use offences but may differ for supply 
offences, or vice versa. No country that varies penalties 
depending on the type of drug involved has set penalties for 
offences involving amphetamine and methamphetamine at 
the lowest level. Of these countries, all except the United 
Kingdom legally class the two drugs equally. Under United 
Kingdom law, amphetamine is in class B while, following 
reports of increased use and production, methamphetamine 
was moved in 2007 from class B to class A, the ‘most 
harmful’ category.
(3) The International Convention on Psychotropic Substances is available online.
Part 1: Overview of amphetamines use in Europe
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Amphetamine and methamphetamine
Amphetamine (CAS-300-62-9) and methamphetamine 
(CAS-537-46-2) are members of the phenethylamine family, 
which includes a range of substances that may be 
stimulants, entactogens or hallucinogens. Thus, 
amphetamine is N,α-methylphenethylamine and 
methamphetamine is N,α-dimethylphenethylamine, or by 
their International Union of Pure and Applied Chemistry 
(IUPAC) systematic names N,α-methylbenzeneethanamine 
and N,α-dimethylbenzeneethanamine, respectively.
Amphetamine
Molecular structure
CH3
NH2
Molecular formula: C9H13N 
Molecular weight: 135.2
Methamphetamine
Molecular structure
CH3
NH CH3
Molecular formula: C10H15N
Molecular weight: 149.2
More information is available on the EMCDDA online drug 
profiles on amphetamine and methamphetamine.
In recent years, the Czech Republic and the United Kingdom 
have introduced restrictions on the sale of cold remedies 
containing pseudoephedrine, as they are purchased to make 
illicit amphetamines. Following reports that 
methamphetamine was being illegally manufactured using 
pseudoephedrine and ephedrine contained in cold and flu 
remedies, the United Kingdom’s Medicines and Healthcare 
Products Regulatory Agency (MHRA) limited from 1 April 
2008 over-the-counter sales of products containing these 
precursors, restricting these to packs containing not more 
than 720 mg pseudoephedrine and 180 mg ephedrine. 
Larger packs would be available on prescription only 
(MHRA, 2008). The Czech National Institute for Drug 
Control also changed from 1 May 2009 the marketing 
authorisation, to restrict over-the-counter medicines 
containing pseudoephedrine (those with up to 30 mg per 
tablet) to a maximum monthly dose of 1 800 mg of 
pseudoephedrine (i.e. 60 tablets, 30 mg each) per person. 
Mail order sales were banned, and supply would be 
monitored via the central database of electronic 
prescriptions. In November 2009, the maximum was 
reduced to 900 mg (30 tablets) of pseudoephedrine per 
single purchase in pharmacies. The restriction was changed 
due to a ban on the use of a central database for electronic 
prescription with regard to issues of personal data 
protection. Importation of medicines containing 
pseudoephedrine from neighbouring countries (Germany 
and, to a greater extent, Poland) has reportedly increased 
greatly since June 2009. This increase is thought to be in 
response to the reduced availability of these medicines 
through Czech pharmacies.
Supply: production and trafficking
Synthetic drugs such as amphetamines tend to be produced 
in or near their consumer markets. Therefore, compared to 
plant-based drugs such as cannabis, heroin and cocaine, 
they are less frequently the subject of transcontinental 
trafficking activities. This, however, may not be true for their 
precursor chemicals, especially ephedrine and 
pseudoephedrine, used for methamphetamine production, 
and 1-phenyl-2-propanone (P2P, or benzyl methyl ketone, 
BMK), which is mostly used to produce amphetamine and 
may also be used to manufacture methamphetamine. Data 
presented in this section, mainly from police sources, can be 
used to build up a picture of the production and trafficking 
activities related to amphetamines and their precursors and 
to describe the products available on the illicit drugs 
markets, their price and purity. 
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Amphetamine
Europe accounted for more than 80 % of all amphetamine 
facilities discovered in 2008, while global seizures of the 
drug in 2008 totalled 23 tonnes, 98 % of which was 
confiscated in two regions, western Asia (14 tonnes) and 
Europe (8 tonnes) (UNODC, 2010). Most of the 
amphetamine seized in western Asia is in the form of tablets 
known as ‘Captagon’, which are reported to contain 
amphetamine trafficked from south-east Europe to the 
Arabian Peninsula (CND, 2009). 
Production of amphetamine in Europe is concentrated in the 
Netherlands, Poland and Belgium, and some is produced in 
Estonia, Lithuania and Germany. In 2008, 39 sites involved 
in the production, tabletting or storage of amphetamine 
were discovered in the European Union and reported to 
Europol: 15 in the Netherlands, 11 in Poland, nine in 
Germany, three in Belgium and one in Lithuania (see 
Figure 1). Of the 39 sites, 28 handled only amphetamine, 
while the remaining 11 handled at least one additional 
synthetic drug, often MDMA. 
Law enforcement agencies in Europe reported more than 
39 000 seizures of amphetamine powder amounting to 8.1 
tonnes of the drug in 2007 (4). This represents the largest 
annual amount of the drug seized, rising from 3.8 tonnes in 
2001. The Netherlands reported an estimated 2.8 tonnes of 
amphetamine seized, representing 34 % of the European 
total, followed by the United Kingdom with 1.8 tonnes 
(22 %), Germany with 0.8 tonnes (10 %), Belgium with 0.5 
tonnes (6 %), and Poland and Norway with 0.4 tonnes 
each (5 %). 
The purity of amphetamine samples intercepted in Europe in 
2008 varied widely. The mean purity of samples ranged 
from less than 10 % in Denmark, Austria, Portugal, Slovenia, 
the United Kingdom, Croatia and Turkey, to greater than 
25 % in Latvia, the Netherlands, Poland and Norway. In 
most of the 17 countries with sufficient data for analysis of 
trends over the past five years, the purity of amphetamine 
has been decreasing or remained stable (5).
In 2008, the mean retail price of a gram of amphetamine 
ranged from EUR 6 to EUR 36 in the 17 reporting 
countries, and it was EUR 9–20 in over half of them. In all 
13 countries reporting data over the five-year period 
2003–08, amphetamine retail prices decreased or 
remained stable (6). 
Global seizures of the precursor chemical P2P increased 
sharply to 5 260 litres in 2008 from 830 litres in 2007 and 
2 600 litres in 2006. Seizures of P2P in the European Union 
increased to 629 litres from 582 litres in 2007. Most of the 
P2P intercepted in 2008 was confiscated in a large seizure 
of 564 litres in Lithuania, while Poland and Estonia reported 
Seizures and market data: sources and 
interpretation
Systematic and routine information to describe illicit drug 
markets and trafficking is limited. Drug seizures are often 
considered as an indirect indicator of the supply, trafficking 
routes and availability of drugs. They are a more direct 
indicator of drug law enforcement activities (e.g. priorities, 
resources, strategies), while also reflecting both reporting 
practices and the vulnerability of traffickers. Data on purity 
and retail prices of illicit drugs may also be analysed in 
order to understand retail drug markets. Retail prices of 
drugs reported to the EMCDDA reflect the price to the user. 
Trends in price are adjusted for inflation at national level. 
Reports on purity, from most countries, are based on a 
sample of all drugs seized, and it is generally not possible 
to relate the reported data to a specific level of the drug 
market. For purity and retail prices, analyses are based on 
the reported mean or mode or, in their absence, the 
median. The availability of price and purity data may be 
limited in some countries and there may be questions of 
reliability and comparability. 
The EMCDDA collects national data on drug seizures, 
purity and retail prices in Europe. Other data on drug 
supply comes from UNODC’s information systems and 
analyses, complemented by additional information from 
Europol. Information on drug precursors is obtained from 
the European Commission, which collects data on seizures 
of these substances in the European Union, and the INCB, 
which is involved in international initiatives to prevent the 
diversion of precursor chemicals used in the manufacture of 
illicit drugs. 
The data and estimates presented in this report are the best 
approximations available, but must be interpreted with 
caution, as many parts of the world still lack sophisticated 
information systems related to drug supply.
(4)  Most recent year with data available from the two countries reporting the largest quantities seized. The data on European amphetamine seizures can be 
found in Tables SZR-11 and SZR-12 in the 2010 statistical bulletin.
(5)  The data on European amphetamine purity can be found in Table PPP-8 in the 2010 statistical bulletin.
(6)  The data on European drug prices mentioned in this section can be found in Table PPP-4 in the 2010 statistical bulletin.
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seizures totalling 39 litres and 22 litres, respectively (INCB, 
2010). Russia, which apparently replaced China as the main 
source of P2P used to manufacture amphetamines in the 
European Union in recent years (EMCDDA–Europol, 2009), 
and where amphetamine is also manufactured illegally 
(UNODC, 2010), reported seizing a total of 2 130 litres of 
the chemical in 2008, or about 10 times more than in 2007 
(191 litres) (INCB, 2010). 
A relatively new trend in P2P trafficking is the ‘masking’ of 
the chemical, which is normally found in liquid form, into a 
powder known as P2P bisulphite, prior to importation into 
the European Union. It should also be noted that some 
European producers of amphetamine, for instance in Poland, 
manufacture their own P2P from so-called ‘pre-precursors’ 
such as phenylacetic acid and benzyl cyanide.
Methamphetamine
World methamphetamine production is concentrated in east 
and south-east Asia and North America, especially Mexico, 
but the drug is also increasingly manufactured in Oceania, 
South and Central America and southern Africa. In 2008, 
18 tonnes of methamphetamine was seized worldwide, 
continuing a stable trend since 2004. Most of the drug was 
seized in east and south-east Asia, notably China, followed 
by North America, particularly the United States (UNODC, 
2010).
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Figure 1: Dismantled illicit amphetamines facilities reported to Europol in 2008
NB: This map displays the approximate location of illicit amphetamine and methamphetamine facilities uncovered in EU Member States in 2008, as reported 
to Europol. 
Where possible, the distribution of reported facilities is presented on a sub-national basis. In the Czech Republic, due to the large number of sites dismantled 
and the lack of information on the location for many of them, a national value is given. One site was also located in the Portuguese Azores Islands. 
Drug type is denoted by the symbol colour, with the number of facilities reported in the country or region indicated. Facilities handling both amphetamine and 
methamphetamine are indicated by two-colour symbols.
Source: Europol.
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Reported seizures of methamphetamine in Europe are small 
in number and quantity compared to those of amphetamine. 
In 2008, law enforcement agencies in 17 countries reported 
about 4 650 seizures totalling 302 kg of methamphetamine. 
Nordic and Baltic countries accounted for more than 95 % 
of all methamphetamine seized in Europe, with Norway 
reporting seizures of 103 kg (34 % of the European total) 
and Sweden 75 kg (25 %), followed by Estonia (38 kg, 
12 %), Latvia (32 kg, 11 %), Lithuania (26 kg, 9 %) and 
Finland (17 kg, 6 %). Despite the large number of 
methamphetamine facilities discovered in the Czech 
Republic (see below), reported seizures amounted to only 
4 kg of the drug (1 % of the European total), equal to the 
amount reported by Germany. The countries reporting the 
largest numbers of methamphetamine seizures in 2008 were 
Norway (1 380) and Sweden (846), followed by Slovakia 
(774), Latvia (494), the Czech Republic (405), Germany 
(356), Lithuania (162) and Finland (120). 
Both the total amount of methamphetamine seized in Europe 
and the number of seizures of the drug have been 
increasing since 2001, with the greatest amount seized 
recorded in 2007 (336 kg) and the highest number of 
seizures in 2008.
The mean retail price of methamphetamine, reported by six 
countries, ranged between EUR 12 and EUR 126 a gram in 
2008. The mean purity of the drug ranged between 22 % 
and 80 % in the 14 countries reporting it, with only three 
countries reporting mean purity levels above 60 %: Belgium 
(80 %), the Czech Republic and Slovakia (both 64 %).
By global standards, illicit supply of methamphetamine in 
Europe is small-scale, and centred around two regions: 
central Europe and the Baltic Sea (EMCDDA–Europol, 
2009). Until recently, methamphetamine production was 
largely confined to the Czech Republic, where 458 mostly 
small-scale production sites were dismantled in 2008 and 
reported to Europol. This is the highest number ever 
reported by the Czech Republic of methamphetamine 
‘kitchen laboratories’, which typically produce a few 
grams of the drug at a time. Small quantities of 
methamphetamine produced in the Czech Republic are 
probably exported to neighbouring countries, especially 
Slovakia and Germany (EMCDDA–Europol, 2009). 
However, seizures of methamphetamine production 
facilities were also reported to Europol in countries 
neighbouring the Czech Republic including Slovakia, 
Germany and Poland (see Figure 1), while Austria 
reported seizing three ‘kitchen labs’ in 2008. It seems that 
methamphetamine supply in central Europe is largely 
organised around small-scale production facilities run by 
users for their own needs and for some limited sales. In 
central Europe, extraction of ephedrine and 
pseudoephedrine from over-the-counter medical 
preparations appears to be the main source of these 
precursors for illicit methamphetamine production.
Large-scale methamphetamine trafficking operations, 
though reported to some extent in central Europe, 
especially in the Czech Republic, are more characteristic 
of a second hub of methamphetamine supply, centred 
round the Baltic Sea. This, probably, more recent supply 
source links the Baltic countries, especially Lithuania and 
Estonia, and possibly Poland, to Scandinavian countries, 
especially Sweden and Norway (but also Russia and 
Belarus), and is reported to involve players trafficking 
larger quantities of methamphetamine (EMCDDA–Europol, 
2009). Although no methamphetamine production 
facilities have been seized in recent years, Lithuania and 
Estonia both report that methamphetamine is 
manufactured on their territories, most likely from P2P 
sourced from outside the European Union. Lithuanian 
nationals have been arrested at border crossings in 
Sweden and Norway smuggling methamphetamine 
shipments weighing about 10 kg, but sometimes as much 
as 50 kg at a time (EMCDDA–Europol, 2009). Lithuanian 
nationals were also involved in many of the seizures of 
P2P that took place in Europe in 2008 and, according to 
Lithuanian authorities, were arrested in connection with 
methamphetamine seizures in Ireland and the United 
Kingdom totalling 6 kg and 8 kg respectively. 
Methamphetamine
Methamphetamine can come in various shapes and forms. 
Powder methamphetamine found on the illicit drugs market 
is similar to powder amphetamine in many ways, including 
purity and appearance, and the two can be 
indistinguishable for both users and dealers. Most users of 
powder amphetamines snort or inject the drug. Crystal 
methamphetamine, in contrast, is often of very high purity. 
It comes in the form of white or translucent crystals, and 
users mostly smoke, snort, or inject it. Methamphetamine in 
tablet form is often mixed with other drugs, and sold as 
‘ecstasy’. Methamphetamine base is an oily paste, which 
may be purified into methamphetamine hydrochloride salt 
or crystals. There is growing evidence that smoking crystal 
methamphetamine has more harmful psychological effects 
and a higher addictive potential than other forms of 
methamphetamine use — probably due to its considerably 
higher purity and route of administration. While use of 
crystal methamphetamine is increasingly prevalent in many 
parts of the world, in Europe, methamphetamine is almost 
exclusively found in powder form. 
14
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Belgium, Portugal and the United Kingdom also reported 
methamphetamine production facilities in 2008, while the 
Netherlands reported the seizure of three storage facilities. 
The INCB reports considerable decreases in world seizures 
in 2008 of two key precursors of methamphetamine: 13 
tonnes of ephedrine in bulk form, down from 22 tonnes in 
2007, and 5 tonnes of pseudoephedrine in bulk form, down 
from 25 tonnes in 2007. EU Member States accounted for 
0.25 tonnes of ephedrine (mainly the Netherlands, Germany 
and Bulgaria), and over 0.5 tonnes of pseudoephedrine 
(almost all in France), but the amounts were small compared 
to the previous year. The INCB warns that global seizures of 
tablets containing ephedrine and pseudoephedrine, which 
are increasingly used to produce methamphetamine in 
Europe and elsewhere, are probably underreported (INCB, 
2010). 
Use of amphetamines in the general 
population
The overall prevalence of amphetamines use in Europe can 
be estimated from general population surveys. Surveys of 
schoolchildren, generally in their mid-teens, provide an 
insight into the use of these substances by young people at a 
vulnerable phase in their development. As levels of 
amphetamines use are low in most countries, targeted 
studies of settings or populations within which higher 
prevalence of amphetamines use can be expected are a 
complementary source of information. 
It is estimated that, overall, around 12 million European 
adults aged 15–64 have tried amphetamines at least once 
in their lives (7) and 1.5 million (1.2 %) young Europeans 
(aged 15–34 years) have used amphetamines during the 
last year. At national level, last year use of amphetamines 
among young adults ranges from 0.1 % to 3.2 %. 
Prevalence levels of more than 2 % have been reported by 
the Czech Republic (3.2 %), Denmark (3.1 %), Estonia 
(2.5 %), the United Kingdom (England and Wales) (2.3 %) 
and Bulgaria (2.1 %) (Figure 2). 
Population surveys suggest that the prevalence of 
amphetamines use across Europe is generally stable, with 
most countries reporting broadly constant levels since the 
1990s (8). Among countries reporting the highest last year 
prevalence levels of amphetamines use in the 15 to 34 age 
group, the United Kingdom has witnessed a long-term 
decline from a high of 6.2 % in 1998 to 2.3 % in 2008/09. 
Denmark, over a similar timescale, reports an increase from 
0.5 % in 1994 to 3.1 % in both 2000 and 2008 (9). 
Prevalence estimates for amphetamines are available since 
2002 for the Czech Republic and 2005 for Bulgaria, the 
only countries to report a change of more than one 
percentage point during the last five years (Bulgaria, from 
0.9 % in 2005 to 2.1 % in 2008; and the Czech Republic, 
from 1.5 % in 2004 to 3.2 % in 2008).
Lifetime prevalence of amphetamines use among 15- to 
16-year-old school students is low across Europe. In 2007 or 
(7)  National prevalence data on amphetamines use presented here are based on general population surveys, which rarely include questions specifically 
about methamphetamine. Methamphetamine is included in the Czech questionnaire, but is not reported separately from amphetamine. In the United 
Kingdom, methamphetamine use was included in the questionnaire for the first time in the 2008/09 British Crime Survey.
(8)  See Figure GPS-8 in the 2010 statistical bulletin.
(9)  In Denmark, the 1994 information refers to ‘problem drugs’, which was considered mainly amphetamines.
Figure 2: Last year prevalence of amphetamines use among young 
adults (15–34 years) in Europe
NB: Data from population surveys, with year of survey are: Czech Republic 
(2008) 3.2 %, Denmark (2008) 3.1 %, Estonia (2008) 2.5 %, United 
Kingdom (England and Wales) (2008/09) 2.3 %, Bulgaria (2008) 2.1 %, 
Norway (2004) 2.0 %, Latvia (2007) 1.9 %, Finland (2006) 1.7 %, Spain 
(2007/08) 1.7 %, Germany (2006) 1.6 %, Sweden (2008) 1.5 %, Poland 
(2006) 1.3 %, Hungary (2007) 1.2 %, Lithuania (2008) 1.1 %, Austria 
(2008) 0.9 %, Ireland (2006/07) 0.8 %, Slovakia (2006) 0.7 %, Netherlands 
(2005) 0.7 %, Italy (2008) 0.6 %, Portugal (2007) 0.4 %, Cyprus (2006) 
0.3 %, France (2005) 0.2 %, Greece (2004) 0.1 %, Romania (2007) 0.1 %. 
For more information, see Figure GPS-5 in the 2010 statistical bulletin.
Sources: National focal points.
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2008, it ranged from 1 % to 5 % in 23 EU Member States, 
Norway and Croatia, with higher levels reported only in 
Bulgaria and Latvia (6 %) (10). Stable trends between 2003 
and 2007/08 can be observed in the lifetime use of 
amphetamines among this population in the majority of the 
countries. An increase by at least two percentage points 
was observed in eight countries, and a decrease of at least 
that amount only in Estonia. 
Use of amphetamines in recreational settings
Europe’s recreational nightlife economy has grown rapidly 
over the past decades, particularly in electronic dance music 
settings. Young people in these settings report prevalence 
levels of stimulant drug use that are generally much higher 
than among the general population. However, the 
proportion of problem drug users may be relatively small, 
and prevalence estimates vary considerably between 
different settings and groups. 
Studies from selected nightlife settings in nine countries in 
2008 reported lifetime prevalence estimates for 
amphetamines use ranging from 5 % to 69 %. Some 
countries have suggested that amphetamines use in dance 
music settings has decreased during the last ten years, with 
the drug losing ground to ecstasy and cocaine powder use. 
An online survey of readers of the dance music magazine 
Mixmag (11) in the United Kingdom in 2009–2010 showed 
that although many of the 2 295 respondents reported 
having used amphetamine (72 % ever, 30 % in the past year 
and 15 % in the past month), other substances are more 
popular. Cocaine powder, for example, was used by more 
respondents to the survey (87 % reported ever use, 83 % 
past-year use and 47 % past-month use). The survey also 
found that while methamphetamine is also present in the UK 
club scene, its prevalence is relatively low, with 6 % 
reporting lifetime use, 1 % use in the last year and 0.3 % 
use in the last month. Viewed in the light of an earlier study 
(McCambridge et al., 2005), there appears to have been no 
change in the prevalence of methamphetamine use in this 
setting. Among men who have sex with men, though, the 
prevalence of methamphetamine use is much higher — a 
study found that about one in five used it in the past year, 
and this prevalence remained stable between 2003 and 
2005 (Bolding et al., 2006).
Antenna studies among young people in Amsterdam show 
that last month prevalence of amphetamine use among 
club-goers peaked at 13 % in 1998, and have since then 
decreased to a level lower than that in 1995 (6 % in 2008). 
Among those reporting use of amphetamine in the last year, 
most use the drug seldom or occasionally (91 %), and often 
together with alcohol (78 %). In contrast to some decades 
ago, in Amsterdam, amphetamine is nowadays almost 
never used in public recreational settings such as bars or 
clubs. The drug is reported to be more commonly used 
during after-parties, for example when cocaine is not 
available, and people usually use less of it compared to 
cocaine or ecstasy. Findings from qualitative studies suggest 
that amphetamine use has been stable for years in some 
specific music scenes (underground, rock, punk, techno, 
hard style) and in rural areas. Its low price makes it 
attractive for users who cannot afford more expensive 
drugs, such as cocaine. Although its popularity is growing 
among young people living in the country or in smaller 
cities, amphetamine has a negative image as a drug of 
‘losers’ who cannot afford good quality drugs. The 
popularity of methamphetamine seems to be even lower 
than that of amphetamine, though it might be growing 
among specific populations, such as men who have sex 
Prevention of amphetamines use
Most universal prevention programmes focus on health 
threats related to tobacco, alcohol and cannabis, and they 
rarely address the use of stimulants such as amphetamines. 
Selective prevention interventions addressing 
amphetamines or stimulants use, however, are available in 
recreational settings. Most of these interventions provide 
information in brochures or print materials, or on the 
Internet, and have not yet been shown to be effective. The 
few evidence-based interventions that are available include 
direct and intensive personal counselling, mainly to 
individuals who may be vulnerable based on behavioural 
factors. While these individuals may not approach regular 
drug treatment services, they may benefit from motivational 
interventions that address their consumption patterns. Other 
types of interventions aim not at drug use itself but at its 
consequences, such as accidents, intoxications and acute 
health problems. These structural interventions, which are 
available in some western European countries (Belgium, 
Denmark, Germany, Spain, Luxembourg, Netherlands, 
Austria, United Kingdom), target nightlife settings, and 
provide transport, chill-out zones, alcohol tests and crisis 
interventions.
(10)  A higher level of lifetime prevalence (8 %) was estimated for Austria, though qualitative follow-up work suggests that some students may have 
misunderstood the question, leading to an overestimation. The real prevalence is believed to be less than 8 %.
(11)  Personal communication, Adam Winstock, King’s College London.
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with men and people who experiment with a wide variety 
of substances. In a survey carried out in 2008, 2.8 % of 
club-goers reported ever use of methamphetamine and 
0.5 % reported last month use of the drug. An internet 
survey targeting students of higher vocational schools and 
universities found 0.43 % lifetime prevalence.
In Czech nightlife settings, the prevalence of pervitin 
(methamphetamine) use is reported to have increased 
between 2000 and 2007. In 2007, almost half of dance 
partygoers reported having used methamphetamine at least 
once in their lives, 28 % in the last 12 months and 16 % in 
the last 30 days. However, in contrast to problem 
methamphetamine users, partygoers in the Czech Republic 
use the drug mostly by snorting or orally, and very few inject 
it. Studies in recreational settings in Slovakia also found 
methamphetamine to be a popular drug. A survey 
conducted in 2005 among attendees of music festivals and 
a big dance music event found that, in the age group 15–29 
years, 27 % had ever used methamphetamine, 19 % in the 
past year and 10 % in the past month.
Health consequences of amphetamines use
Research on the health consequences of amphetamines use 
has largely been conducted in countries such as Australia 
and the United States, where methamphetamine use, 
notably crystal methamphetamine smoking, has become an 
important problem. While the findings of these research 
efforts may sometimes be more specific to drug use 
patterns that are uncommon in Europe, in many instances 
they are applicable to users of powder amphetamines, 
including injectors. In addition to reports in the 
international literature, results from recent, sometimes 
smaller-scale, studies reported by European countries are 
included in this overview.
Medical use of amphetamines has been associated with a 
number of side-effects including anorexia, insomnia and 
headaches, but illicit amphetamines use is associated with 
a broader set of negative consequences (Darke et al., 
2008), including psychosis, cardiovascular and 
cerebrovascular problems, dependence, psychological and 
psychiatric problems, infectious diseases and death. For 
example, in the Czech Republic, a survey assessing 
hospitalisations among patients who had been admitted at 
least once for drug use disorders found that for pervitin 
(methamphetamine) users, the three most common 
diagnostic groups — apart from dependency-related 
conditions — included mental and behavioural disorders; 
injury, poisoning, other consequences of external causes; 
and infectious diseases. 
Polydrug use, particularly with drugs that potentiate the 
cardiovascular effects of amphetamines, such as alcohol, 
opioids and cocaine, increases the toxicity of 
amphetamines. 
Short-term negative effects of amphetamines
Amphetamines use, particularly at higher doses, may bring 
about restlessness, tremor, anxiety, dizziness, tension, 
irritability, insomnia, confusion, aggression, and, in some 
individuals, psychotic symptoms and panic states. As 
intensive amphetamines use often occurs in binges, a ‘crash’ 
or coming down is a common after-effect among users. A 
crash may last from several hours to several days, with 
symptoms such as depression, fatigue and sleeping 
difficulties. Suicidal behaviour is a significant risk during the 
crash period (Pates and Riley, 2010).
Psychological and psychiatric effects of long-term 
amphetamines use
Causal links between amphetamines use and psychiatric 
symptoms are difficult to establish, as some symptoms and 
conditions may pre-exist in the user or other factors, such as 
HIV infection or polydrug use, may act as cofounders. 
Studies have found, however, that pre-existing psychotic 
symptoms can be greatly exacerbated by subsequent 
amphetamines use. For example, a Swedish study among 
prisoners (Håkansson et al., 2009) revealed that users of 
amphetamines were more likely to exhibit psychiatric 
symptoms than were heroin or cocaine users. They also 
found that many stimulant users had had other psychiatric 
problems as well, and drug use exacerbated these 
problems.
The most serious psychopathological harms associated 
with amphetamines use include psychosis, depression, 
suicidal behaviour, anxiety and violent behaviour (Darke et 
al., 2008). Psychosis induced by amphetamines is typically 
transient, involves delusions and hallucinations, and is 
similar to paranoid schizophrenia. It lasts for hours to days, 
and in severe cases may require hospitalisation and 
medication. Regular users of amphetamines commonly 
experience various psychotic symptoms, including feelings 
of persecution and auditory, visual and tactile 
hallucinations (such as a perception of parasites in the 
skin). In contrast to early studies, which attributed the onset 
of psychosis to pre-existing conditions, recent research 
shows that amphetamines use may cause psychosis. 
Psychosis, however, is not an inevitable consequence of 
amphetamines use, but its likelihood is dramatically 
increased by heavy use of the drug (Darke et al., 2008; 
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Pates and Riley, 2010). Amphetamines users often suffer 
from depression and have high rates of suicidal ideation 
and attempted suicides. 
In Slovakia, specialised dependence centres treating 
methamphetamine users reported a high occurrence of 
psychotic disorders of a schizophrenic character among 
their clients. These disorders were predominantly short-term 
drug-induced psychoses with hallucinations and delusions 
of persecution, which quickly resolved with abstinence. In a 
few cases, however, long-term treatment with neuroleptic 
medication was necessary. Furthermore, at admission, 46 % 
of clients were found to have symptoms of depression 
according to the Beck Depression Inventory. Czech experts 
looked into routine data collected on psychiatric diagnoses 
and found a higher prevalence of psychosis among 
methamphetamine users than among users of other drugs. A 
survey among addiction specialists also suggested the need 
for specific treatment procedures in users who experience 
psychosis or certain psychotic symptoms. Many 
methamphetamine users report having experienced anxiety 
symptoms before starting to use the drug, and still more 
report severe anxiety symptoms since commencing use. 
Users, though, might mistake the symptoms of anxiety for 
methamphetamine-induced hyperarousal (Darke et al., 
2008). Self-mutilation after amphetamines use sometimes 
happens in both humans and animals, but is it less common 
among women than among men (Pates and Riley, 2010). 
Violent behaviours are also common among 
psychostimulant users, especially among chronic users and 
those with acute intoxication. Such behaviours might also 
accompany psychosis (Darke et al., 2008). Establishing a 
causal relationship between methamphetamine use and 
violence may, however, be unfounded because most 
evidence comes from cross-sectional studies (Tyner and 
Fremouw, 2008). 
Another important mental health consequence of 
amphetamines use is dependence. Amphetamines 
withdrawal symptoms are different from those of depressant 
drugs, such as opioids or alcohol, where the symptoms are 
the opposite of the acute pharmacological effects of these 
drugs. On the contrary, some features of psychostimulant 
withdrawal symptoms, particularly agitation and 
hyperarousal, mimic those of intoxication. Other symptoms of 
amphetamines withdrawal include fatigue and inertia, 
hypersomnia followed by protracted insomnia, and an onset 
of agitation with mood disturbances that range from 
dysphoria to severe clinical depression (Jenner and 
Saunders, 2004). Central nervous system recovery after 
hyperstimulation by these drugs is characterised by excessive 
sleeping, eating and irritability (Pates and Riley, 2010).
A Latvian study investigated the severity of dependence 
among amphetamines and opioid users, using the Severity 
of Dependence Scale, which focuses on the psychological 
components of dependence. The study showed that heroin 
users experienced a higher level of severity of dependence 
than amphetamines users.
Both the occurrence and the severity of mental health 
problems among amphetamines users are associated with 
longer duration of use, more frequent use, dependence 
and injecting (Pates and Riley, 2010). Mental health 
problems are further associated with schizoid personality 
Neurocognitive damage and its consequences
Underlying the effects of amphetamine and 
methamphetamine are the similarities in chemical structure 
they share with the brain’s natural neurotransmitters 
dopamine and norepinephrine (Melichar and Nutt, 2010). 
In the brain, amphetamines affect the monoamine 
neurotransmitter systems (dopaminergic, serotonergic, 
noradrenergic and glutamatergic) (Nordahl et al., 2003). 
Amphetamines are, however, neurotoxic and can cause 
damages that may last for months after cessation of use. 
Many core behavioural and psychiatric symptoms, 
including withdrawal, that occur in heavy users of the drug 
are likely to be related to altered monoamine regulation 
(Darke et al., 2008). Moreover, cognitive deficits in 
methamphetamine users are well-documented: these mainly 
involve impairments in episodic memory, executive 
functions, information processing speed and small 
impairments in motor skills, language and 
visuoconstructional abilities (Scott et al., 2007). 
Neurological and cognitive impairment can reduce users’ 
independence in daily life, for example in preparing meals 
or managing money. This is further associated with 
depressive symptoms. In addition, as many treatment 
interventions available for amphetamines users are 
cognitive-based, neuropsychological deficits in substance 
users may result in poor treatment outcomes, such as higher 
rates of programme rule violation, poor cognitive skill 
acquisition and dropping out (Scott et al., 2007). Social-
cognitive functioning may also be impaired, possibly as a 
result of damage to the frontal lobes. In methamphetamine 
users, impaired social functioning is linked with other 
symptoms such as paranoid ideation, depression, 
aggression, and a need to hide, all of which can eventually 
lead to social isolation. This is in contrast to the original 
intention of the users to enhance their social interaction. In 
animal experiments, rats and monkeys display similar social 
withdrawal, which suggests a physiological basis rather 
than a wish to hide because of the social undesirability of 
drug use (Homer et al., 2008).
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prior to the onset of use, or with a family history of 
schizophrenia, especially in the non-transient, psychotic 
condition. Violent behaviours may occur more frequently 
in people with an existing propensity to violence (Darke et 
al., 2008). 
Cardiovascular and cerebrovascular effects
A review by Kaye et al. (2007) summarises the acute and 
chronic cardiovascular pathology associated with 
amphetamines use. The most common cardiovascular effects 
of amphetamines use are an acute increase in heart rate 
and blood pressure, which may abate without further 
consequences in the majority of cases. Nevertheless, in the 
context of chronic use or pre-existing cardiovascular 
pathology, these changes in cardiovascular functioning may 
trigger serious and potentially fatal events.
Amphetamines users are at elevated risk of cardiac 
pathology, including serious events such as unstable angina, 
and myocardial ischaemia and infarction. The risk is not 
likely to be limited to the duration of drug use, because the 
chronic cardiovascular pathology associated with 
amphetamines use may make the side-effects of the drug use 
more long-lasting. The risks are greatest among chronic 
amphetamines users, and pre-existing cardiac pathology, 
due to amphetamines use itself or to other factors, increases 
the risk of an acute cardiac event. 
Psychostimulant-induced cerebrovascular problems are also 
well recognised. Studies report an increase in the risk of 
ischaemic and haemorrhagic stroke, and a substantially 
higher associated risk of death linked to such events (Darke 
et al., 2008).
It is impossible to assess the risk of serious cardiac events 
solely on the basis of dose and level of use, as other factors 
may also play an important role. For this reason, information 
on potential cardiovascular complications related to 
amphetamines should be targeted to all users, not just 
dependent and chronic users. 
Other health effects
Other health effects and risks include neurotoxicity (12), risks 
associated with driving, dental disease, and maybe foetal 
growth restriction associated with amphetamines use during 
pregnancy. Alterations in brain structure and chemistry 
have been documented in heavy users of illicit 
amphetamines, although the clinical implications of these 
findings remain uncertain (Chang et al., 2007). 
Epidemiological data on the risks associated with the use of 
amphetamines when driving are rare and inconsistent 
(EMCDDA, 2008). Methamphetamine use has been 
associated with poor oral hygiene, including severe tooth 
decay and tooth wear (Hamamoto and Rhodus, 2009). 
Methamphetamine use causes xerostomia (dry mouth) and 
bruxism (teeth clenching and grinding), leading to rampant 
caries as users neglect their dental hygiene while frequently 
consuming carbonated sugary beverages. While some 
studies on amphetamines and pregnancy found insufficient 
evidence to evaluate the developmental toxicity of 
therapeutic amphetamines (Golub et al., 2005), another 
study found a 3.5 fold increased risk of foetal growth 
restriction among babies of women using methamphetamine 
during pregnancy (Smith et al., 2006).
Infectious diseases among amphetamines users
Little is known about the prevalence of infectious diseases 
among groups that use different types of drugs. It has been 
shown, though, that high levels of sexual risk-taking among 
amphetamines users (both injectors and non-injectors) may 
contribute to an increased risk of HIV and sexually 
transmitted infections (Degenhardt et al., 2010). 
Infectious diseases such as HIV and hepatitis B or C are 
more prevalent among injecting drug users than among 
the general population or among non-injecting drug users 
(Mathers et al., 2008; Wiessing et al., 2008a, b). In 
contrast to some countries further east (Russia, Ukraine), 
in the central and western parts of the European Union 
amphetamines are almost exclusively purchased in 
powder form, associated with lower injecting risks 
compared to drugs acquired in liquid form (Hartnoll et al., 
2010). Amphetamines injectors may be a group where 
injecting risk is combined with elevated sexual risk 
behaviour. However, this risk combination is not always 
reflected in the seroprevalence of infections, as the 
predominance of injection-related versus sex-related 
infection risks may be different in different populations.
Most European studies of infectious diseases among users 
of amphetamines have been conducted on injectors using 
amphetamines as their main or only drug. These studies 
show a mixed picture: while some found no difference in 
infection prevalence, others found a lower prevalence of 
both risk behaviours and HIV and hepatitis infection 
among amphetamines injectors than among heroin 
injectors. Differences in infection prevalence are not 
(12) See the box ‘Neurocognitive damage and its consequences’.
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necessarily due to the drugs as such, but may be due to 
other factors, such as isolated networks of lower-risk drug 
injecting groups within the injecting population (Shaw et 
al., 2010).
In the Czech Republic, a national hepatitis C virus (HCV) 
study found no difference in the estimated incidence of 
HCV infection between ‘pervitin’ (methamphetamine) 
users and opioid users, after adjustment for the period of 
injecting drug use. Routine infectious disease testing data 
from low-threshold facilities, however, as well as the data 
available from the register of treatment demands, suggest 
that pervitin users may have a lower incidence of HCV. 
This difference, though, may be attributable to the 
younger average age and shorter history of injecting 
drug use of pervitin users in those samples. In 
comparison to the general population and to opioid 
users, pervitin users report a higher rate of sexual risk 
behaviour, making them more vulnerable to sexually 
transmitted infections. 
Slovakia reported that there is a significantly lower 
prevalence of HCV (likely also reflecting different incidence) 
among users injecting methamphetamines (26 % testing 
antibody positive) compared with those injecting opioids 
(59 % positive), although the data were not adjusted for the 
length of use. Furthermore, the lower frequency of injecting 
by amphetamines users compared to heroin users results, on 
average, in a significantly lower risk of bloodborne 
transmission among amphetamines injectors over a given 
period of injecting. In the opinion of the Slovak experts, this 
difference in injecting frequency might explain a large part 
of the difference in HCV prevalence.
A study in Estonia compared 256 primary opioid (fentanyl) 
injectors with 75 primary amphetamines injectors (Talu et 
al., 2010). One of the main findings was that the prevalence 
of HIV among those who injected amphetamines (27 %) was 
less than half that among those who injected fentanyl 
(62 %). Self-reported risk behaviours were consistent with the 
seroprevalence findings and less common among 
amphetamines users than among fentanyl users. Fentanyl 
users had injected almost five times more frequently in the 
last four weeks, they had shared needles or syringes with 
persons who were known to be HIV-positive four times more 
often, and they filled their syringes from other used syringes 
almost three times more often. While levels of unprotected 
sex were not statistically different among amphetamines and 
fentanyl users, amphetamines injectors had more sexual 
partners in the past 12 months.
A study in Latvia found also lower levels of prevalence of 
HIV, HCV and hepatitis B virus among amphetamines 
injectors than among opioid injectors.
In the United Kingdom’s unlinked anonymous surveillance 
system, where injecting drug users in contact with services are 
sampled in repeated surveys, injectors of crack cocaine, 
cocaine powder and amphetamines were more likely than 
injectors of other drugs to self-report having shared needles in 
the past four weeks (HPA, 2009). As HIV prevalence in this 
study was very low (around 1 %), this difference in risk 
behaviours did not translate into a difference in HIV infections.
Preventing and reducing harms related to 
amphetamines injecting
Interventions to reduce drug-related health harms among 
amphetamines injectors focus on preventing injecting-
related infections. However, few amphetamines-specific 
measures exist, and responses rely mainly on what is 
known from HIV prevention among opioid users. 
Interventions offered to injecting amphetamines users are 
similar to those provided for injectors of other drugs and 
are delivered in the same settings. In general, these 
interventions include the distribution of leaflets describing 
the risks of infectious diseases and other health problems; 
practical skills in connection with safer drug use; needle 
and syringe programmes; safer sex education and condom 
promotion; referral to voluntary counselling and testing for 
infections; and referral to drug treatment as well as other 
health care as needed (Grund et al., 2010a). 
Interventions may also reflect local amphetamines use 
patterns. For example, a new intervention developed and 
tested at low-threshold agencies in the Czech Republic 
supports non-injecting and less harmful patterns of stimulant 
use by distributing empty gelatine capsules to pervitin 
(methamphetamine) users. The users may fill the capsules 
with pervitin powder and swallow them. Taken orally, 
amphetamines have a high bioavailability, and the 
capsules enable the user to avoid the bitter taste of pervitin. 
Clients perceived preparing the capsules easy and showed 
increasing interest in this alternative route of administration. 
More research is still needed to evaluate its benefits and 
potential harms.
Risk behaviours are also associated with the characteristics 
of the drug users’ social networks and their environments. 
To prevent and reduce harms related to amphetamines 
injecting, a combination of interventions may be required, 
aiming at reducing personal risk behaviours, changing 
social network norms (about risk boundaries or equipment 
sharing) through peer education, addressing the injecting 
process (e.g. by promoting the use of one-piece instead of 
two-piece syringes) and structural factors (e.g. by 
increasing the availability of sterile syringes or providing 
hygienic injecting environments as an alternative to public 
injecting). 
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Deaths related to amphetamines
Little is known about deaths related directly (acute 
poisoning) or indirectly to amphetamines. A recent 
systematic review suggests that investigating the morbidity 
and mortality associated with amphetamines use should be 
a research priority and that cohort studies with long-term 
follow-up and data that are linked to mortality statistics are 
needed (Singleton et al., 2009). This is particularly 
important for countries where problematic amphetamines 
use is prevalent or increasing. 
A comprehensive review of studies on mortality among 
dependent and problematic amphetamines users included 
eight cohort studies in Australia, Thailand, Sweden, Finland, 
Netherlands, Czech Republic (Singleton et al., 2009). The 
estimated crude mortality ratio ranged from zero in Australia 
to 2.95 per 1 000 person years in Thailand, and, among 
the European countries, from 0.49 to 2.89 per 1 000 
person years. The standardised mortality ratio (the ratio of 
observed deaths to the expected deaths in the general 
population) was estimated in the Czech cohort study only 
(6.22 overall). A study in the Czech Republic also found that 
the overall mortality rate of pervitin users was approximately 
half that among heroin users (4.9 cases versus 8.6 cases per 
1 000 person year, respectively). 
In Latvia, a mortality cohort study enrolled 551 patients who 
entered treatment for amphetamines use between 1999 and 
2006. For the cohort, the crude mortality rate was 5.69 per 
1 000 person years, and the standardised mortality rate 
was 3.28 per 1 000 person years. These rates have to be 
interpreted with caution because of the very low number 
(nine) of deaths reported during the follow-up period.
Only three of the studies reviewed by Singleton et al. 
described the specific causes of death. These mainly 
included heroin overdose and accidents or injuries. In the 
Czech Republic, pervitin users appear to show a higher 
rate of deaths caused by external factors, especially 
suicides, when compared to opioid users. A study among 
drug users from the Netherlands found higher mortality 
rates among injectors than among non-injectors, and 
among those who had used amphetamines for five years or 
longer (van Haastrecht et al., 1996). Estimating the 
mortality directly associated with amphetamines is 
complicated by polydrug use (i.e. concurrent use of mainly 
heroin and cocaine). 
An overview of drug-related deaths in the United Kingdom 
between 1997 and 2007 identified 832 deaths with positive 
tests for amphetamine or methamphetamine (Schifano et al., 
2010). Only in 13 % of these fatalities was just one drug 
found at post mortem or implicated. In these cases, the most 
common causes of death were due to well-known medical 
consequences of amphetamines use such as cerebral 
haemorrhage and acute hypertensive crisis (70 %), pre-
existing cardiovascular and cardiopulmonary conditions 
(17 %) and risky behaviour while intoxicated with 
amphetamines (8 %). In the other cases, the drugs 
mentioned in addition to amphetamines included heroin or 
morphine (39 %), alcohol (20 %), methadone (17 %), 
cocaine (13 %). Methamphetamine was identified in only 14 
out of the 832 cases.
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Amphetamines use exists to some extent in all European 
countries, but only in a few is it reported as a major 
component of the drug problem (Figure 3). This section of 
the report reviews the available information regarding 
problem amphetamines use and the related treatment 
responses in four geographical regions and sub-regions of 
Europe: western and southern Europe, where, in many 
countries, amphetamines users account for a small fraction 
of problem drug users; northern Europe, where 
amphetamines use is sometimes a long-established problem 
and is still today a key element of the drug situation; eastern 
and central Europe, where there are very different levels of 
amphetamines problems, but with increasing trends in 
several countries, with a special focus on the Czech 
Republic and Slovakia, as countries that have a specific 
historical context and comparable amphetamines problems.
Western and southern Europe
There is no single history of amphetamines use in western 
and southern Europe, as during the twentieth century it 
developed along different timelines across these regions. In 
addition, historical information is available only for a few of 
these countries. In the absence of information on southern 
European countries, reports of past amphetamines use in the 
Netherlands and the United Kingdom must serve to illustrate 
the history of amphetamines in western Europe (13). 
During World War II, amphetamine and methamphetamine 
tablets were widely distributed to members of the armed 
forces on both sides of the conflict. The literature specifically 
mentions German soldiers, but servicemen of other nations 
also received amphetamines pills. Three-milligram 
methamphetamine pills under the name pervitin were 
already available in Germany from 1938, and appear to 
have been widely distributed among the armed forces. In 
1941, this substance became more controlled in that country, 
due to the long recovery periods that soldiers needed after 
its use and some cases of abuse. Thereafter, German 
military doctors prescribed it more cautiously.
In the United Kingdom, after the war, amphetamines were 
liberally prescribed, with ready availability of over-the-
counter preparations. This policy was later changed, and 
the substances became subject to prescription control in 
1957. The 1960s saw an increase in amphetamines use in 
Europe, as the drugs were taken up by new groups of 
recreational users. A Dutch ethnographic study on problem 
Part 2: Problem amphetamines use in Europe
Figure 3: Problematic use of amphetamines in Europe
NB: This map highlights those countries with significant problem 
amphetamines use, grouped according to the relative levels of amphetamine 
and methamphetamine use by a multi-indicator approach. Other countries 
contributing to the special data collection (or in the case of Germany, 
showing significant treatment demand related to these drugs) are also 
indicated.
Mainly amphetamine
Mainly methamphetamine
Both drugs present
Countries with problematic
amphetamines use 
Other countries 
Reporting additional information
or covered in some detail
Not covered in detail
(13) With further information on the use of amphetamines by armed forces in the Second World War, available on Wikipedia.
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drug users suggests that amphetamine and 
methamphetamine were used in specifi c drug scenes, 
together with other drugs, in the Netherlands since 1962. In 
the United Kingdom, recreational use of diverted 
amphetamines is said to have ‘reached epidemic 
proportions’ in the 1960s, and towards the end of the 
decade there were some reports of methamphetamine 
injecting on the London drug scene.
During the 1970s, many countries imposed or tightened their 
control on amphetamines possession and/or use. In 1971, 
the United Kingdom scheduled non-injectable amphetamines 
as class B and injectable amphetamines as class A under its 
Drug Misuse Act. However, due to the focus on heroin use 
during the 1970s and 1980s, information about 
amphetamines use in the United Kingdom at that time is 
scarce. It is known, though, that amphetamine remained 
popular in the nightlife scene, and pills were replaced by 
amphetamine powder. In 1976, the Netherlands issued its 
‘Amphetamine Decree’, placing amphetamine and 
methamphetamine under the Opium Act as illegal drugs. As 
in the United Kingdom, amphetamines were ‘not a priority of 
drugs combat’, partly as they were not perceived to cause 
serious problems and partly because of the focus on opioids.
In these countries, the available information suggests that 
though amphetamines use continued during the 1970s and 
1980s, it was overshadowed by the rising use of heroin. In 
the 1990s, however, with the development of the electronic 
music scenes and the diffusion of synthetic drugs, 
amphetamines use surged.
Problem amphetamines use today
In the majority of western and southern European countries, 
problem amphetamines use represents a small fraction of 
problem drug use and primary amphetamines users account 
for less than 5 % of those who enter treatment for opioids, 
cocaine or amphetamines problems in most countries of this 
region (14). The fi gure is higher only in Belgium (14 %), 
Germany (13 %) and the Netherlands (10 %) (Figure 4). 
Most amphetamines clients enter treatment in outpatient 
services. Their mean age is 29.1 years, and they started 
using amphetamines at an average age of 19.3 years. The 
male to female ratio among amphetamines users in this 
group is about 2:1. Among amphetamines users in these 
countries, injecting ranges from zero (Ireland, Italy, Cyprus, 
Luxembourg, Austria) to 24 % (United Kingdom). Between 
2003 and 2008, the number and proportion of clients 
entering treatment for primary use of amphetamines 
remained mainly stable in most western and southern 
European countries.
Low prevalence of amphetamines use among problem drug 
users has also been reported in various national and local 
studies. The Dutch ‘Amsterdam Cohort Study’ revealed that 
neither amphetamines alone (around 1 %) nor the 
combination of amphetamines with heroin or cocaine (about 
8 %) was prevalent among the studied population of 
problem drug users. Similarly, in Wales, a study in 2008 
among the users of a needle exchange programme found 
that 8 % of clients used amphetamines, while Luxembourg 
reports that only 1 % of problem drug users sampled in 
various treatment and non-treatment settings consider 
amphetamines as their main drug. Compared with the low 
levels of amphetamines use reported by problem drug users 
in this part of Europe, a survey carried out in 2004 stands 
out as an exception, with almost half the injectors (48 %) 
(14) Data on treatment prevalence — on all drug users in treatment — may yield a slightly different breakdown by primary drug: see Table TDI-38 in the 2010 
statistical bulletin.
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Figure 4: Relative importance of amphetamines, opioids and 
cocaine clients entering treatment in selected European countries 
NB: The pie charts show the number of amphetamines, opioids and cocaine 
users entering specialised drug treatment as a proportion of the total number 
of those reporting one of these three drugs as their primary substance. Data 
are shown only for countries where amphetamines (or non-cocaine stimulants 
in the case of Germany and Lithuania) account for at least 2 % of those 
entering treatment for these three drugs. Based on Table TDI-5 (part ii) in the 
2010 statistical bulletin and non-TDI data for Norway. 
Source: National focal points.
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attending a needle and syringe programme in Antwerp, 
Belgium, reporting use of amphetamines.
A study conducted in Luxembourg showed that 
amphetamines use may have been part of problem drug 
users’ consumption careers in the past, but is less often part 
of their current drug use patterns. Among sampled 
participants, both from treatment and other settings (low-
threshold facilities and prisons), 57 % had ever taken 
amphetamines, but less than 5 % — mostly participants 
under the age of 30 — reported taking the drug in the past 
two months. Among respondents from prisons who reported 
having used amphetamines, 86 % had not used the 
substance in the last two years. 
Treatment options for problem amphetamines use
In western and southern European countries, specific 
treatment programmes for amphetamines users are rare and 
treatment systems have specialised in responding to the 
needs of opioid users, especially with opioid substitution 
treatment. In some cases, amphetamines users, especially 
socially integrated ones, may regard these treatment 
services as suitable only for users of ‘problem drugs’ such as 
heroin (EMCDDA, 2009). They may also believe that 
treatment facilities are unable to adequately deal with the 
complexities of amphetamines dependence (e.g. Vincent et 
al., 1999; Wright et al., 1999). For these reasons, they may 
be reluctant to seek treatment for their drug problems.
Besides the general outpatient psychosocial interventions, 
residential treatment or referral to psychiatric services are 
available for serious psychiatric comorbidity associated with 
problematic amphetamines use. The United Kingdom is the 
only country where substitution therapy with 
dexamphetamine is available. Dexamphetamine has long 
been available for the treatment of highly problematic users 
of amphetamines in England and Wales, where it may be 
prescribed by any doctor. Information on this practice is 
limited. A survey of pharmacy services conducted over 10 
years ago estimated that 900 to 1 000 clients were 
receiving this treatment (Strang and Sheridan, 1997). Most 
Treatment for amphetamines problems
The number of drug users reported entering treatment for 
primary amphetamines use in Europe is relatively small (1), 
amounting to about 19 000 across 28 countries in 2008, half 
of them entering drug treatment for the first time in their lives. In 
addition, amphetamines are reported as a secondary drug, 
often in combination with opioids, by around 36 000 treatment 
entrants who report other primary drugs. 
Amphetamines withdrawal is not considered life-threatening, 
and successful detoxification is possible (Jenner and Saunders, 
2004). Apart from a few studies showing some effectiveness 
for fluoxetine (an antidepressant) and imipramine (an 
adrenergic uptake inhibitor; Shoptaw et al., 2009a, b; 
Srisurapanont et al., 2001), most pharmacological approaches 
for treating amphetamines problems are still under development 
and evaluation. Contingency management (2), however, has 
been shown to result in a reduction of use while in treatment 
and in abstinence at short-term follow-up (Roll et al., 2006).
Despite the lack of effective pharmacological treatment options 
for amphetamines users to reduce use or maintain abstinence, 
some Member States have developed specific interventions 
targeting problem amphetamines users. 
Short-term detoxification and a range of outpatient 
psychosocial interventions, such as cognitive behavioural 
therapy, are provided, and pharmacological treatment of 
symptoms, as well as long-term residential treatment, is 
available for the more severe cases. Unfortunately, as reported 
by professionals, psychiatric problems are frequent and difficult 
to handle within the therapeutic context. 
Specific quality assessment measures for the treatment of 
amphetamines users have been reported by a number of 
Member States. In countries where problem amphetamine use 
has been widespread for a long time, quality assurance is 
integrated in general drug treatment programmes. 
Research on treatment options for drug dependence has 
historically focused on the needs of opioid users, but research 
in the field of amphetamine and methamphetamine is growing, 
especially regarding potential substitution therapy. Such 
research is urgently needed, as professionals report 
experiencing therapeutic difficulties with amphetamines users. 
Sharing of best practice can also play an important role in 
improving care, particularly in countries lacking specialised 
treatment services for stimulant users.
(1)  In a small number of countries, it is not possible to distinguish amphetamines users in the treatment data, as these are reported as users of 
‘stimulants other than cocaine’. Data from the other countries indicate, however, that amphetamines users may represent the vast majority (86 %) 
of this category, and they are included in the amphetamines data for analysis. 
(2)  Contingency management typically aims to reduce the reinforcing effects of drugs by rewarding abstinence with vouchers or other incentives that 
increase progressively, but may also decrease or be lost.
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prescriptions were issued by doctors working in hospitals or 
clinics, almost all of whom were in the National Health 
Service (NHS). A survey of 265 NHS specialist services, 
carried out in 2000, revealed that dexamphetamine 
prescribing was available in about a third of the services 
surveyed (Rosenberg et al., 2002). Due to a lack of 
demonstrated effectiveness, however, the United Kingdom 
guidelines on clinical management of drug dependence 
recommend against substitute prescribing of 
dexamphetamine (NTA, 2007).
Northern Europe
Problem amphetamines use lies at the heart of the drug 
problem in Sweden and Finland, while in the neighbouring 
countries of Denmark and Norway, levels of use of these 
substances in the general population are above the 
European average. Amphetamines use in northern Europe 
has some specific historical characteristics, which can be 
described in some detail for Sweden (Goldberg, 1968) and 
Finland.
Amphetamine drugs were introduced in Sweden in 1938 
under the names benzedrine (amphetamine) and pervitin 
(methamphetamine). In the following two to three years, the 
substances were widely recommended in the Swedish mass 
media as a ‘pep pill’ for all sorts of people from students to 
tired housewives, and soon reached their broadest public. 
Sweden was probably the first country in Europe to conduct 
representative surveys of students’ drug use. In studies 
carried out in 1938–1941, about 70–80 % of students 
reported lifetime prevalence of amphetamines use. From 
1939, amphetamines were no longer available in Sweden 
without a doctor’s prescription; which stabilised levels of use 
for one year, before they started to rise again. In 1942/43, 
the number of amphetamine users was estimated to be 
200 000, or 3 % of the adult population, most of whom 
were occasional users, though 7 200 were estimated to use 
at least once a week, with about 1 % (200) of all 
amphetamine users using between 10 and 100 pills a day. 
In 1943, as awareness increased about the negative 
side-effects of amphetamines, a warning was issued to 
Swedish physicians, and the mass media started to point out 
the risks of uncontrolled use. This led to sales decreasing by 
40–60 %. The following year, Sweden placed amphetamine 
on its National Narcotic Drugs List. In spite of this, 
widespread use of these substances continued until the early 
1950s, when it became more closely associated with certain 
social groups such as artists and criminals.
In 1960, Sweden estimated that there were 1 000 
amphetamine injectors in the country. The spread of 
amphetamine use in Sweden continued afterwards at 
reportedly higher rates. The user groups expanded beyond 
artists and criminals, and the drug gained ground in 
recreational settings as well — young people in parties and 
persons wishing to improve their sexual performance. 
Finland, in 1941, received a large supply of 
methamphetamine pills from Germany in support of the 
Continuation War against the Soviet Union (1941–44). 
When the ensuing offensive was at its height, 850 000 
pervitin pills were available to Finnish front-line soldiers, 
commanders and reconnaissance patrols as well as 
medical crops. Pervitin was used to reduce the need for 
sleep and sensitivity to hunger, and to improve the 
physical performance of soldiers. It also dulled their 
sensitivity to pain, while heightening their alertness, 
increasing their self-confidence and concentration, and 
lowering their threshold to taking risks. However, the 
side-effects of this drug soon became obvious. 
Sleeplessness due to pervitin use could induce paranoia, 
hallucinations and aggressive behaviour, while long-term 
use increased the likelihood of substance addiction and 
could even lead to fatalities. 
During and after the war, many Finnish families used various 
prescription amphetamine and methamphetamine products 
(benzedrine, stimulan, pervitin and beramin). Amphetamines 
were particularly popular among drivers and students. The 
substances were readily prescribed, and as 
methamphetamine was not considered a narcotic, it was not 
monitored. Problem drug use, at that time, was equated 
mainly with the use of opioids in Finland. However, in the 
mid-1950s, as opioid use decreased, amphetamine use 
began to increase, possibly as a result of the influence of 
Sweden on the post-war Finnish generation. Amphetamine, 
even at that time, was often used intravenously, and the first 
cases of problem amphetamines use in Finland were 
documented. Postulated reasons for this include relatively 
easy access to liquid amphetamine and Finnish drug use 
practice’s history of favouring intravenous drug use in order 
to experience the strongest effects. However, it was not until 
the late 1960s, that amphetamine became more widely 
known in Finland, and amphetamine began to be smuggled 
into Finland.
In 1974–75, Sweden witnessed the arrival of heroin in the 
Stockholm area, where it became displaced amphetamine 
as the drug of choice among injectors. Outside the capital, 
however, amphetamine retained its popularity. In the 1990s, 
some countries in the region experienced a further increase 
in amphetamines use, both in recreational settings and 
among problem drug users. In Finland, amphetamine use 
has outstripped opioid use since 1997, with use and 
drug-related harm probably peaking in the mid-2000s. 
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Problem amphetamines use today
Finland has produced an estimate of 14 500–
19 000 problem drug users in 2005 (15). Of these, 75–80 % 
used amphetamine as their primary drug, corresponding to 
16 296 (12 000–22 000) problem amphetamine users, or 
4.7 (3.4–6.3) per 1 000 inhabitants aged 15–64. Although 
subnational studies suggest lower prevalence levels of 
problem drug use in eastern and northern Finland, the 
proportion of amphetamine users is roughly the same across 
the country. In the greater Helsinki area, the estimated 
number of problem amphetamine users was 4 000–6 000 
in 2005. The estimated prevalence of problem amphetamine 
use in Finland increased steadily between 1997 and 2005. 
Primary users of amphetamines mostly enter treatment in 
outpatient centres, although in Finland and Sweden, 
inpatient centres play an important role (16). Amphetamine 
users represent less than a fifth of treatment entrants citing 
opioids, cocaine or amphetamines as their primary drug in 
Denmark (17 %), around a quarter in Norway (25 %) (17) 
and Finland (26 %) and almost half in Sweden (49 %) 
(Figure 4). Injecting drug use is reported by a clear majority 
of amphetamines clients attending outpatient centres in 
Finland (82 %) and Sweden (67 %), but not in Denmark 
(4 %), thereby highlighting differences in patterns of 
amphetamines use between these countries. 
While the number of amphetamines users entering treatment 
for the first time has remained relatively stable between 
2003 and 2008 in Sweden and Denmark, Finland reports a 
decrease in both the number and the proportion of new 
amphetamines clients (18).
Sweden reports the highest average age of amphetamines 
clients in Europe (35 years), followed by Finland (30 years), 
while in Denmark clients for this drug are younger (26 
years). Sweden (1.5:1) and Finland (1.6:1) report two of the 
lowest male to female ratios among amphetamines clients in 
Europe. Overall, female amphetamines clients are younger 
than their male counterparts. In Sweden, 37 % and in 
Finland 25 % of all women entering outpatient treatment use 
amphetamines as their primary drug, compared to 27 % 
and 17 % of men, respectively. In these two countries, 
especially among women in Sweden, the duration between 
first use and first treatment is long compared to the rest of 
Europe (19).
Of the 6 350 drug users who entered prison in Sweden in 
2006, 4 750 were diagnosed with a severe drug 
dependence problem. Most of them (73 %) were primary 
amphetamines users, which is a much higher proportion 
than is found among drug using populations outside prison. 
These amphetamines users exhibited an intensive use 
pattern: 61 % were daily users, with an average 23 days of 
use in the past 30 days, and most of them (70 %) injected 
the drug. Many of them reported also using other drugs in 
the past 30 days (38 %), mainly cannabis (36 %) and 
tranquillisers (22 %), or were binge alcohol drinkers (12 %). 
The use of opioids, cocaine or hallucinogens was rare. 
Amphetamines users were older, came from a more rural 
and non-immigrant background, and reported psychiatric 
symptoms and problems more often and previous inpatient 
detoxification less often than users of heroin or other drugs.
A Norwegian study interviewing clients of a needle 
distribution facility in Oslo found that in the period between 
1999 and 2008, 63 % of the interviewees used 
amphetamines on 14.5 days on average during the last 
month. The distinction between amphetamine and 
methamphetamine was not possible, as the users were unable 
to distinguish between the two. A trend analysis revealed an 
increase both in the proportion reporting amphetamines use 
during this period (from 59 % to 68 %) and in the number of 
days of amphetamines injecting (from 12.5 to 16.6 days). 
High proportions of amphetamines users reported polydrug 
use, with 77 % having also used cannabis and 20 % cocaine; 
75 % having injected heroin in the last month. 
Polydrug use appears to be a common pattern among 
problem amphetamines users. A Finnish study found that 
amphetamines users usually engage in polydrug use to 
achieve specific pharmacological effects. Alcohol, 
cannabis, medications or buprenorphine were often used 
either to boost or alter the effects of amphetamines or to 
enable sleep following extended hours of hyperactivity and 
wakefulness. Moreover, amphetamines and opioids may 
be used intermittently, either when the other drug is not 
available or to ‘treat’ dependence on one drug by the 
other drug. Among injecting drug users attending a needle 
exchange programme in Malmo (Sweden), 57 % of the 
clients considered amphetamines to be their main drug. 
The study, which focused mainly on illicit buprenorphine, 
also found that amphetamines users used buprenorphine 
(15)  The problem drug use estimate in Finland must be interpreted with caution when comparing it with figures from other countries. This is because the Finnish 
estimates may be based on a broader definition than that of the EMCDDA (and of other countries) and may include some occasional users as well.
(16) See Table TDI-19 (part ii) and (part iv) in the 2010 statistical bulletin.
(17) Based on non-TDI data for Norway.
(18) See Table TDI-3 in the 2010 statistical bulletin.
(19) See Table TDI-103 (part iii) in the 2010 statistical bulletin.
26
EMCDDA 2010 Selected issue
more often than heroin users. In another Swedish study 
carried out in 2007/08 among injecting drug users 
recruited from public settings in Stockholm, 47 % of 
respondents identified amphetamines as the drug they had 
used most frequently in the last 12 months. Polydrug use 
was common and some primary users of other drugs used 
amphetamines too. 
Norwegian emergency psychiatry data from 2003 and 
2006, mainly on people with acute psychosis characterised 
by uncontrolled behaviour and suicidality, showed that of 
those who tested positive for amphetamines, most (in 2003) 
or all (in 2006) were positive for methamphetamine. While 
this may suggest that methamphetamine plays more of a role 
in psychosis than amphetamine, it may also reflect the 
underlying prevalence of use of the two drugs. Toxicological 
data from the National Institute of Public Health provides 
evidence of the increasing presence of methamphetamine in 
Norway. Over the period 2000–08, amphetamines were 
detected in 3–5 % of urine samples from correctional 
facilities 18–28 % of blood samples from drivers suspected 
of driving under the influence, and 5–8 % of autopsy 
samples, with data from all three sources pointing to the 
same changes in the stimulants market. For all categories, as 
a proportion of all cases involving amphetamines, those with 
methamphetamine have risen from being almost zero 
around the turn of the millennium to 54 % (prisoners), 69 % 
(drivers), and 80 % (autopsies) of all tests in 2008. These 
laboratory results are mirrored by the number of seizures of 
these two substances. In 2000, methamphetamine only 
accounted for 6 % of the total seizures of the two drugs, 
rising to 44 % in 2008, and as high as 68 % in the first six 
months of 2009.
In Sweden, analysis of biological samples taken from people 
suspected of minor drug offences in 2009 showed that 
methamphetamine was found in about 1 % of the tests, 16 % 
of the tests revealed amphetamine alone, and both drugs 
were detected in a further 13 % of tests. The prevalence of 
any amphetamines among those tested also declined from 
44 % in 2006 to 34 % in 2009. However, between 2007 
and 2008, the proportion with both drugs present increased 
about three-fold to 12 %. While this appears to indicate an 
increase in the use of methamphetamine at the expense of 
amphetamine, further interpretation is difficult, as 
amphetamine is a metabolic breakdown product of 
methamphetamine (Schepers et al., 2003). Other data from 
the police and customs in Sweden also show an increase in 
methamphetamine use in most parts of the country. Many 
users in Sweden are reported to find methamphetamine 
interchangeable with amphetamine, but some view 
methamphetamine as stronger and better. The two 
substances probably cost about the same and are distributed 
by the same criminal groups. Methamphetamine smoking 
has not been reported in Sweden.
A series of Finnish studies found that amphetamines users 
usually take 0.5 to 5 grams of the drug per day, depending 
on the purity and individual tolerance levels. As the price of 
a gram of amphetamines is around EUR 30, problem 
amphetamines use can be costly and is often associated 
with petty theft. 
Treatment options for problem amphetamines use
In Sweden, amphetamine is the drug historically most 
commonly associated with problem drug use and treatment 
of drug dependence has been developed to cater for the 
needs of amphetamine users. The main treatment approach 
is residential treatment using the 12-step Minnesota model. 
Problem amphetamine users attend a 6 month 12-step 
programme, and then attend Narcotics Anonymous 
meetings for several years. Residential treatment is usually 
provided by private organisations, but is covered by the 
national health insurance. Clients with less problematic use 
receive psychosocial treatment, namely cognitive 
behavioural treatment and motivational interviewing, on an 
outpatient basis. A clinical trial with naltrexone, a non-
selective opioid antagonist, to reduce craving for and use of 
amphetamines has been conducted with positive outcomes 
reported. 
In Finland, problem amphetamines users are sometimes 
admitted to psychiatric hospitals to receive treatment for 
amphetamine psychosis. However, no long-term psychiatric 
care is available for such users. Psychosocial interventions 
and short-term detoxification are available, but access to 
continued treatment is much more limited. When seeking 
treatment, some amphetamines users are thought to 
emphasise their use of opioids in order to receive long-term 
opioid substitution treatment. 
Norway reports that problem amphetamines users are often 
difficult to reach with therapeutic measures and many of 
them do not seek help. However, this group still constitutes a 
large proportion of those admitted to emergency psychiatric 
treatment.
Eastern and central Europe
In several eastern and central European countries, various 
data sources suggest that the use of amphetamines 
represents a significant part of overall problem drug use. 
This section focuses on five countries: Estonia, Hungary, 
Latvia, Lithuania and Poland in this region; the Czech 
Republic and Slovakia are discussed later. Unfortunately, 
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little has been reported regarding the social history of 
amphetamines use in these five countries. Available studies 
mostly place the first appearance of amphetamines use in 
the 1990s. For example, a Polish study looked at the 
emergence of amphetamines use in Gdansk (Sękiewicz, 
2001), a city that has been characterized as being the first 
to be influenced by new ‘western lifestyle’ trends. It found 
that the Polish drug scene was dominated by ‘kompot’ (also 
known as Polish heroin) in the 1970s and 1980s. The early 
1990s saw the rise of problems related to the use of 
amphetamines. Although the number of amphetamines users 
in Gdansk in contact with treatment agencies increased 
greatly in the 1990s, a snowball survey suggested that only 
4 % of all amphetamines users had contact with the 
treatment system, as opposed to about half of the heroin 
users. Amphetamines users were also more socially 
integrated than heroin users.
Problem amphetamines use today
Primary use of amphetamines was reported by between 3 % 
(Lithuania) and 41 % (Hungary) of treatment entrants 
declaring opioids, cocaine or amphetamines as their 
primary drug (Figure 4). The number and proportion of 
amphetamines clients entering treatment for the first time in 
their lives increased rapidly in Latvia (from 1 % in 2000, to 
16 % in 2003 and 38 % in 2008); the percentage also 
increased in Hungary, but with decreasing absolute 
numbers.
Most primary users of amphetamines entering treatment do 
so in outpatient settings. In Hungary, most amphetamines 
clients are sent to treatment by the criminal justice system as 
diversion from punishment. In Latvia, most are self-referred 
or referred by medical services.
The average age of amphetamines users entering treatment 
in these countries is low compared to other countries: 
between 22 (Estonia) and 28 years old (Hungary) 
depending on the country. Overall, female amphetamines 
clients are younger than their male counterparts (20). On 
average, primary amphetamines clients report their first use 
of the drug at between 17.4 years (Estonia) and 21.5 years 
(Hungary).
Females account for about a third of those entering 
treatment for primary amphetamines use, a higher 
proportion than among opioid or cocaine clients. In Estonia, 
Lithuania and Latvia, more than 60 % of amphetamines 
clients report injecting the drug, while 23 % do so in 
Hungary.
Annual surveys have been conducted since 2006 among 
drug users recruited from non-treatment settings in Riga, the 
capital of Latvia. In 2009, the most commonly used drug 
was amphetamines: 65 % of the respondents reported using 
it in the past 30 days, almost all (98 %) by injection. The 
prevalence of amphetamines use decreased with age. 
Amphetamines users were less likely than heroin users to 
switch to other drugs.
In Latvia, amphetamine has been detected in various 
biological samples from police sources, first in 1991 and 
increasingly since 1998. Methamphetamine was first 
detected in 1999 and increasingly since then. Evidence of 
polydrug use is common among amphetamines users tested, 
with almost 80 % of the samples showing signs of 
amphetamine or methamphetamine use testing positive for at 
least one other substance. The drugs most commonly 
detected in the presence of amphetamines are opioids, 
cannabis and benzodiazepines and/or barbiturates.
An Estonian study among injecting drug users in two cities 
found amphetamine injecting quite widespread. In 2007, 
half of the injecting drug users in Tallinn and a quarter of 
those in Kohtla-Jarve reported injecting amphetamine in the 
past four weeks and a third and 16 %, respectively, 
considered amphetamine as their primary drug. A survey 
carried out in 2008 among clients of syringe exchange 
services found that over half of them had injected 
amphetamine in the past four weeks. Another study found 
that 63 % of amphetamine injectors had injected only this 
drug within the last four weeks, while the remainder had 
also injected other drugs. Among prison inmates, more than 
two-thirds reported using amphetamine while incarcerated 
in 2006 and 2008.
A third study in Estonia used respondent-driven sampling 
(Talu et al., 2010) to compare HIV-related risks among 
amphetamine versus opioid (fentanyl) injectors (21). The study 
found that primary amphetamine users were more likely than 
fentanyl users to be Estonian, to have a shorter injecting 
career, and to have health insurance, and they were less 
likely to be daily injectors in the past four weeks and to have 
been arrested in the past 12 months. The study also found 
that, in the past four weeks, almost half of the primary 
fentanyl users had also used amphetamine, while a quarter 
of primary amphetamine users had also used fentanyl.
(20) See Table TDI-103 (part iii) in the 2010 statistical bulletin.
(21) See ‘Infectious diseases among amphetamines users’.
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A Hungarian study on out-of-treatment injecting drug users 
in Budapest, self-identified either as Roma or non-Roma, 
found that amphetamine had the highest levels of both 
lifetime and past-30-day prevalence in this group: in the 
past 30 days, 83 % of Roma and 61 % of non-Roma 
injectors had used amphetamine, mostly with other 
substances. Another Hungarian survey conducted between 
2006 and 2008 among clients of a syringe exchange 
programme in Budapest showed that amphetamine was the 
most frequently reported primary substance, namely by 
58 % of males and 64 % of females. Amphetamine was 
used more frequently by younger participants and women. 
A third study, conducted in 2005/06 among injecting drug 
users recruited in a different area of Budapest, found that in 
the past 30 days, 52 % injected heroin only, 20 % 
amphetamine only, and 27 % both heroin and amphetamine 
(Gyarmathy et al., 2009b). None of those interviewed 
reported using methamphetamine or tested positive for its 
metabolites (Gyarmathy et al., 2009a).
A 2008 survey in various Polish low-threshold facilities 
revealed that in the past 30 days, 76 % of the respondents 
(who were mainly in their twenties) had used opioids and 
61 % had used amphetamines. Over two-thirds of 
amphetamines users reported using the drug at least once a 
week, and 11 % used it daily. The most prevalent route of 
administration of amphetamines was injecting (85 %), while 
20 % snorted it, 7 % used it orally and 1 % smoked the 
drug. Altogether, 17 % of respondents identified 
amphetamines as the drug causing them the most problems. 
In a 2007 survey among Polish prison inmates, 39 % of 
respondents reported ever in lifetime use of amphetamines, 
15 % use in the last year and 5 % use in the last 30 days. 
Last year prevalence of amphetamines use decreased 
considerably with age. 
Treatment options for problem amphetamines use
Many countries in this group have experienced surges of 
problem amphetamines use only recently. Thus, their 
treatment systems are still largely organised to serve the 
needs of problem opioid users, and they appear to 
experience difficulties and shortcomings in addressing the 
needs of amphetamines users. 
In Estonia, treatment options for problem amphetamines 
users are also reported to be relatively limited. However, 
with a planned update of the national drug strategy in 
2010, more attention will be given to this group. In Hungary 
the first professional protocol dealing specifically with the 
treatment of amphetamines users was published by the 
Ministry of Health at the beginning of 2008. The protocol 
covers diagnosis, the indicated structure of medically 
assisted and drug-free treatment, and other therapies and 
rehabilitation.
Czech Republic and Slovakia
Methamphetamine use, including use of crystal 
methamphetamine, has developed as a major problem in 
several regions of the world, but has had up to now limited 
diffusion in Europe. A different methamphetamine problem, 
however, developed in the former Czechoslovakia, and is 
still central to the drugs problem of the Czech Republic and 
Slovakia (Grund et al., 2010b; ACMD, 2005). 
In the former Czechoslovakia, non-alcohol drug use 
consisted mainly of diverted medications, both stimulants 
and depressants. In the 1950s, benzedrine problem use 
and dependence was considered the most serious non-
alcohol substance dependence problem. At about this time, 
Amphetamine injection in countries bordering 
the European Union 
In Ukraine, reports indicate a high prevalence of both 
methamphetamine and methcathinone (a stimulant drug 
manufactured from pseudoephedrine) use among injecting 
drug users and a growing concern about it among 
professionals (Grund et al., 2010a). Stimulants were 
reported as the second most popular drug in a study by 
Balakireva et al. (2006), and there was a 69 % prevalence 
of past-month use among of out-of treatment injecting drug 
users in a study by Booth et al. (2008). A worrying trend 
was found in case of methcathinone (called locally 
‘boltushka’), which seemed to be increasing in popularity 
among very young and poor users in the city of Odessa. 
Manufactured from phenylpropanolamine in the absence of 
ephedrine or pseudoephedrine, it might have many 
negative health impacts, including haemorrhagic stroke 
(Chintalova-Dallas et al., 2009; Horwitz et al., 2000).
Most injecting drug users in Russia inject only heroin, but 
amphetamines are reported to be the second most 
frequently injected drug. In a study involving injecting drug 
users from 11 Russian cities, depending on location 
between 15 % and 89 % of the participants reported 
having injected stimulants at some point in their lives, with 
from zero to 43 % of them doing so in the past 30 days. 
Altogether, 90 % of the participants reported having 
injecting heroin in the past 30 days (Borodkina et al., 
2005). Few injectors seem to use amphetamines only (e.g. 
less than 5 % of injecting drug users in St Petersburg; 
Grund et al., 2010b).
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non-medical use of other preparations containing 
amphetamines or amphetamines precursors was also 
reported, including yastil (an asthma medication containing 
ephedrine). Sometimes, benzedrine and yastil were used 
together. As yastil’s non-medical use was also linked to 
psychotic symptomatology, the drug was soon made 
prescription-only.
Towards the end of the 1950s, a Czechoslovak factory 
started to produce the amphetamines-based medicines 
phenmetrazine (preludin) and dexphenmetrazine. Although 
these drugs were intended for weight loss and the treatment 
of fatigue, depression and narcolepsy, their non-medical use 
is reported in the late 1950s. Consumption of the drugs 
increased greatly between 1959 and 1960, especially 
among students and professional drivers. By 1963–65, 
phenmetrazine dependence accounted for around 40 % of 
drug users treated in inpatient psychiatric facilities. 
As a response to the increasing number of reported cases of 
dependence in the 1970s, Czechoslovakia made the first 
steps to regulate phenmetrazine and dexphenmetrazine by 
requiring a prescription for their purchase. During the same 
period, manufacturing of methamphetamine in kitchen labs 
and injecting of the drug emerged. Patterns of 
amphetamines use began to diverge between what is now 
the Czech Republic and Slovakia, though the two countries 
were united until 1993. In what is now Slovakia, only a few 
small groups, mainly artists and university students, were 
known to use amphetamines, among several other drugs. In 
what is now the Czech Republic, small closed groups of 
users organised around methamphetamine producers, and 
by the late 1980s an estimated 25 000–30 000 users were 
dependent on non-alcohol drugs, principally pervitin. This 
figure is comparable to the most recent estimates of problem 
drug use in the Czech Republic.
With the emergence of a pervitin black market in 
recreational settings, the period since 2000 has seen 
pervitin use in the Czech Republic expand beyond small 
closed user groups. At the same time, recreational pervitin 
use spread in Slovakia, where problem methamphetamine 
use became extensive around 2004.
Problem amphetamines use today
The number of problem methamphetamine users in the 
Czech Republic in 2008 was estimated to be 21 200 
(20 700–21 800), corresponding to a prevalence of 2.87 
per 1 000 inhabitants aged 15–64 years (2.79–2.94 per 
1 000), and showing no significant change during the 
period 2001 to 2008 (22). Methamphetamine users 
constitute about two-thirds of the problem drug users in the 
country, with the remainder using opioids as their principal 
drug. Most problem drug users in the Czech Republic 
inject their drug. The prevalence of problem drug use is 
highest in the capital city Prague. However, the estimated 
4 300 problem methamphetamine users make up only 
about a third of problem drug users in the city, whereas in 
the rest of the country they account for 80 % of problem 
drug users.
The most recent national estimate for Slovakia put the 
number of problem drug users in 2007 at 8 083 (5 783–
15 742), corresponding to 2.1 (1.5–4.0) cases per 1 000 
inhabitants aged 15–64. This represents a stable situation 
since 2005, which recent data suggests may have continued 
in 2008. Subnational estimates by substance are not 
available, but analysis of treatment demand indicator data 
suggests that outside the capital city, Bratislava, 
methamphetamine users make up a higher proportion of all 
problem drug users entering treatment. 
Methamphetamine is reported as the primary drug by a 
large number and proportion of clients entering treatment in 
the Czech Republic (4 700 clients, or 70 % of those entering 
treatment for amphetamines, cocaine or opioids) and 
Slovakia (545 clients, 39 %) (Figure 4). Among those 
entering treatment for the first time in their lives, the 
proportions are higher (23). Between 2003 and 2008, the 
number of first-time treatment entrants for problems relating 
to methamphetamine use increased in the Czech Republic 
and, especially, in Slovakia (24).
A large proportion of methamphetamine users in the Czech 
Republic enter treatment in low-threshold services or in 
psychiatric outpatient and inpatient services (25). 
Considerable differences are reported between the different 
regions in the two countries. This may reflect differences not 
only in the extent of the drug problem, but also in the 
availability of treatment and other factors.
Methamphetamine users entering treatment in the Czech 
Republic and Slovakia are, on average, younger (25–26 
years) than opioid clients (29 years). The male to female 
ratio of methamphetamines clients is close to unity in the 
Czech Republic (1.3:1), whereas in Slovakia male clients 
(22) See Table PDU-102 in the 2010 statistical bulletin.
(23) See Table TDI-5 (part i) and (part ii) in the 2010 statistical bulletin.
(24) See Table TDI-3 in the 2010 statistical bulletin.
(25) See also ‘Treatment options for problem amphetamines use’, below.
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outnumber females by 3.4 to one. The number of women 
entering treatment for primary methamphetamine use in the 
Czech Republic is reported to be increasing, especially 
among the younger age groups (26).
Injecting is reported as the main route of drug administration 
by 80 % of methamphetamine clients in the Czech Republic 
and by 36 % in Slovakia, though it is less frequently 
reported among those entering treatment for the first time in 
their lives (27). Of methamphetamine outpatient clients in the 
Czech Republic, 43 % report using the drug occasionally, 
39 % 1–6 times a week, and 18 % daily (28), while in 
Slovakia, 8 % report using it occasionally, 61 % 1–6 times a 
week, and 31 % daily (29). Use of other drugs, mainly 
heroin, cannabis and alcohol, is also often reported by 
primary users of methamphetamine. In addition, both 
countries report that the use of methamphetamine as a 
secondary substance is common, especially among heroin 
users in substitution treatment.
Methamphetamine users form the largest group of clients 
(53 %) of low-threshold facilities in the Czech Republic. 
Polydrug use is also common among these clients, with a 
sizeable proportion (16 %) using pervitin in combination 
with opioids. In Slovakia, a high proportion of drug users in 
contact with low-threshold programmes in 2008 reported 
using methamphetamine, either as their sole drug (35.4 %) 
or in combination with heroin (14.7 %).
Treatment options for problem amphetamines use
In the Czech Republic, which has a long history of 
problem methamphetamine use, detoxification is the 
primary treatment for methamphetamine dependence. In 
most cases, it is covered by universal health insurance. 
Detoxification is provided in inpatient treatment units 
associated with psychiatric departments within drug 
treatment or medical facilities that are either public or run 
by a non-governmental organisation. Unless severe 
physical withdrawal symptoms are observed, 
detoxification does not require specific pharmacological 
treatment. Symptomatic therapy with antipsychotics is only 
recommended in indicated cases. Detoxified patients can 
be referred to either outpatient services or residential 
rehabilitation, which include a wide range of psychosocial 
interventions from cognitive behavioural therapies to 
therapeutic communities.
In order to investigate whether certain aspects of treatment 
services are adapted to meet specific characteristics of 
methamphetamine users, a series of surveys among nearly 
30 psychiatric, counselling and drug treatment facilities 
were conducted. The surveyed health professionals 
considered that the therapeutic process related to 
methamphetamine dependence does not differ much from 
that of other substance-related dependencies. According to 
respondents from outpatient treatment centres, pervitin users 
tend to underestimate the severity of their drug problem, and 
thus lack the motivation to change. First contacts are often 
associated with a crisis and crisis interventions. Pervitin users 
tend to drop out of treatment soon after admission or a few 
contacts. Professionals also reported that most pervitin users 
are relatively young and often have family-related problems, 
so it is common to work within a family therapy context. 
Older pervitin users are reported to have a more 
problematic polydrug use patterns and their conditions are 
often complicated by psychotic symptomatology, which 
worsens the therapeutic prognosis.
Staff surveyed from detoxification centres reported similar 
experiences. According to them, pervitin users are often 
referred to the detoxification centres involuntarily (for 
example, through criminal justice referrals) in a state of 
acute toxic psychosis, which is typically accompanied by 
aggressiveness towards both themselves and their 
environment. Patients often need to be restrained; 
communication with them is difficult, and they usually reject 
any care. 
In Slovakia, the relatively recent upsurge of 
methamphetamine use negatively affected opioid users’ 
methadone maintenance treatment, as a considerable 
proportion of clients were also methamphetamine dependent 
when they entered the treatment. Being dependent on two 
drugs may counteract the effects of methadone on illicit 
opioid use. Many stabilised or abstinent patients also started 
using methamphetamine. As a consequence of these two 
elements, 12-month retention in methadone treatment 
dropped from 77 % in 1999 to 46 % in 2003 — the period 
that corresponds to the upsurge of the methamphetamine 
epidemic in Slovakia. In response, the methadone 
maintenance programme in Bratislava developed a new 
harm reduction modality, to complement the therapeutic 
one. In the former, clients using methamphetamine were not 
excluded from treatment, but received a maximum daily 
dose of 40 mg of methadone and were not required to 
(26) See Tables TDI-21 (part ii) and TDI-103 (part i) and (part iii) in the 2010 statistical bulletin.
(27) See Table TDI-5 (part iii) and (part iv) in the 2010 statistical bulletin.
(28) According to the TDI Protocol, occasional use means that the drug was not used in the month prior to entering treatment.
(29) See Table TDI-111 (part v) and (part vi) in the 2010 statistical bulletin.
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become abstinent. The introduction of this new modality 
appears to have halted the drop in retention, which in 2008 
improved to 54 %. About three to four times as many 
patients are enrolled in the therapeutic modality as in the 
harm reduction one, and only a few want to be transferred 
to the latter. On the other hand, patients of the harm 
reduction modality may be referred to the therapeutic 
modality based on their condition and motivation.
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Focusing on countries where amphetamine or 
methamphetamine is an important part of the drug problem, 
this Selected issue has attempted to trace the historical 
development of amphetamines use since the introduction of 
these substances as medicines in the 1930s. The history of 
the use of these substances is the result of an interplay of 
global forces, such as the rapid spread of recreational drug 
use in the 1960s and the arrival of heroin on the European 
drug scene in the 1970s, and local events such as the rise of 
small-scale pervitin (methamphetamine) production in what 
was then Czechoslovakia. The outcome of this is that the 
present day amphetamines situation across Europe is 
marked by strong national characteristics, possibly more so 
than any other of the major illicit drugs.
Production of amphetamine in Europe appears to be situated 
primarily in the Netherlands, Poland and Belgium, and to a 
lesser extent in Estonia, Lithuania and Germany. By global 
standards, illicit supply of methamphetamine in Europe is 
from local small-scale ‘kitchen labs’ to limited international 
trafficking, and is centred around two regions: central 
Europe (especially the Czech Republic) and the Baltic Sea.
It is important to note that while crystal methamphetamine 
and meth smoking are increasingly prevalent in many parts 
of the world, methamphetamine in Europe is available 
almost exclusively in powder form, and thus is virtually 
indistinguishable from amphetamine in appearance and 
effect. Recent data from countries in the north of Europe 
show that amphetamine could be increasingly replaced by 
methamphetamine on the markets of some Scandinavian 
and Baltic countries.
General population surveys and surveys among school 
students show a relatively low prevalence of amphetamines 
use in most European countries, but in at least five countries 
it is estimated that more than 2 % of young people (15–34) 
have used the drug in the last year. Much of the less 
problematic use of amphetamines takes place in recreational 
settings, particularly around dance music events, where use 
of the drug appears to be more closely associated with 
certain music genres. Ever in lifetime use of amphetamines 
among young people in such settings varies considerably, 
with levels of up to 30–70 % recorded in some studies in the 
Czech Republic, Hungary, Slovakia and the United 
Kingdom. Over the long term, there are signs that, at least in 
some countries, amphetamines may have lost ground in 
nightlife settings to cocaine or ecstasy, or new substances 
such as mephedrone. 
In western and southern European countries, problem 
amphetamines use is rare but can reach a certain level of 
importance in some countries and among specific 
populations of problem drug users. Contrastingly, in many 
northern, eastern and central European countries, 
amphetamines users, often injecting, make up a sizeable 
proportion of the problem drug using population. In this 
wide geographical area, several distinct sub-patterns 
emerge. The most obvious are the enduring amphetamine 
problem in Sweden and Finland and the historical 
methamphetamine problem in the Czech Republic, which is 
also affecting Slovakia. Other countries in these regions are 
also affected, including Estonia, Lithuania, Latvia and 
Norway, where amphetamines are often injected, and 
Denmark where the drug is reported to be mainly snorted.
Withdrawal from amphetamines is not considered life-
threatening, and successful detoxification is possible. Across 
Europe, the treatment options available for amphetamines 
users often reflect the national patterns and history of 
problem amphetamines use. In western and southern 
European countries, treatment systems have specialised in 
responding mainly to the needs of opioid users, especially 
with opioid substitution treatment. In northern and central 
European countries with a long history of treating 
amphetamines use, some programmes are directed towards 
the needs of amphetamines users. In some other central and 
eastern European countries, significant problem 
amphetamines use is more recent. Thus, treatment systems in 
this area have primarily developed services for problem 
opioid users and appear to experience difficulties and 
shortcomings in addressing the needs of amphetamines 
users.
Conclusions
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